In Brief
Refine Search
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Biotechnology
Swedish Orphan Biovitrum, also known as Sobi, today announced an executive appointment. 2 February 2023
Pharmaceutical
Roche’s shares dipped 1.4% to 322.60 francs this morning, when the Swiss pharma giant announced that, in full-year 2022, it achieved sales growth of 2% (+1% in Swiss francs) to 63.3 billion francs ($.66.8 billion), but warned that 2023 profits would see a downturn. 2 February 2023
Biotechnology
In the UK, two new marketing authorizations have been granted by the country’s medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA). 2 February 2023
Pharmaceutical
As the British pharmaceutical industry gets ready to negotiate the reimbursement regime in the country, representatives have expressed dismay at a move to raise the statutory revenue clawback rate. 2 February 2023
Biotechnology
Canadian mRNA-focussed biotech firm Providence Therapeutics today announced the appointment of Robert Georgantas III as president and chief technology officer (CTO). 1 February 2023
Generics
Mumbai, India-based generic drugmaker Lupin Limited revealed that it has received tentative approval from Food and Drug Administration (FDA), under the US President’s Emergency Plan for AIDS Relief (PEPFAR), for its New Drug Application for dolutegravir, emtricitabine and tenofovir alafenamide (DETAF) tablets. 1 February 2023
Biotechnology
UK-based Orbit Discovery, which calls itself a ‘leader in the discovery of therapeutic peptide hits’, has announced a collaboration. 1 February 2023
Pharmaceutical
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has led on a joint consultation on proposed amendments to the MHRA’s statutory fee, which will come into effect on April 1 this year. 1 February 2023
Pharmaceutical
Swiss pharma giant Novartis presented its financial results for the fourth quarter and 2022 as a whole on Wednesday morning. 1 February 2023
Pharmaceutical
British pharma major GSK outperformed expectations with its annual financial results statement, reporting sales of £29.3 billion ($36.1 billion) for the year, an increase of 19%, driven by revenues of £7.4 billion in the final quarter. 1 February 2023
Pharmaceutical
Danish diabetes care giant Novo Nordisk today reported that sales for full-year 2022 increased by 26% in Danish kroner and by 16% at constant exchange rates to 177.0 billion kroner ($25.6 billion) in 2022, slightly ahead of analysts’ expectations of 176 billion kroner. 1 February 2023
Biotechnology
US biotech giant Amgen released mixed financial results for the fourth quarter and full year 2022 versus comparable periods in 2021, after markets closed on Monday. 1 February 2023
Pharmaceutical
The life sciences industry in Australia has called for better funding for the country’s medicine and technology regulator. 31 January 2023
Pharmaceutical
US drugmaker Pfizer cemented its place at the top of the pile of global pharma companies in delivering its 2022 financial results. 31 January 2023
Pharmaceutical
The UK health technology assessor the National Institute for Health and Care Excellence (NICE) , has been recommended for reimbursement for USA-based Jazz Pharmaceuticals’ Epidyolex (cannabidiol,100mg/mL oral solution), for adjunctive therapy of seizures associated with tuberous sclerosis complex (TSC), for patients two years of age and older. 31 January 2023
Biosimilars
Two decades and more than $200 billion later, AbbVie has finally lost its exclusive hold on the US market for biologics based on Humira (adalimumab). 31 January 2023
Biotechnology
Dutch gene therapy company uniQure and University of Massachusetts Medical School (UMMS) spin-out Apic Bio have entered into a global licensing agreement for APB-102 to treat superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS), a rare, genetic form of ALS. 31 January 2023
Pharmaceutical
Pharma companies participating in the 340B drug pricing program in the USA do not have to provide medicines ad nauseam to contract pharmacies. 31 January 2023
Biotechnology
mRNA specialist CureVac has reported positive data from key Phase I programs in COVID-19 and seasonal flu. 31 January 2023
Biosimilars
Biologic products have revolutionized the treatment options for many diseases and typically carry favorable benefit–risk profiles compared with small molecule drugs. 31 January 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze